Glendale, Ariz. – As thousands gathered Sunday for Charlie Kirk's memorial service at State Farm Stadium, many attendees spoke about the ways in which Kirk has inspired them and continues to wield ...

And just like that, July is packing up its sunshine and saying goodbye. It brought the heat—literally and figuratively—and lifestyle brands didn’t miss a beat. From trail-ready running shoes that ...

New rules to let state-registered investment advisors publish testimonials and online reviews from their clients have been proposed by the North American Securities Administrators Association (NASAA), ...

Robustgoods.com has emerged as a complement to the tech giants within a sleek minimalism and proprietary design industry. This brand is known for its rugged, repairable, and aesthetically consistent ...

In 2024, RealTrends listed Mile High Lifestyles as the No. 10 large team in Colorado and included it among the top 500 large teams in the U.S. for a sixth straight year. Since its founding in 2018, ...

Intra-Cellular Therapies' Caplyta shows strong sales growth and label expansion potential, making it a valuable acquisition for Johnson & Johnson at $14 billion. JNJ's acquisition of ITCI is strategic ...

In an Instagram video posted ahead of her upcoming Netflix series, the Duchess of Sussex announced her brand’s new name and its revamped focus. By Katie Van Syckle Meghan, the Duchess of Sussex, has ...

Just a month after trial results appeared to dampen prospects for the use of intra-arterial thrombolysis on top of stroke thrombectomy in patients with large-vessel occlusions (LVOs), two new trials ...

When you live in the wealthiest city in the world, it’s not hard to come up with people you suspect have access to their parents’ money. But when we set out to put faces to the generational wealth ...

The purchase will allow Johnson & Johnson to delve further into the treatment of central nervous system disorders. The purchase is one of several transactions in recent years to boost its ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...

Intra-Cellular Therapies, Inc. announced a settlement with Sandoz Inc. regarding patent litigation involving their product CAPLYTA® (lumateperone). This litigation arose from Sandoz's attempt to ...